Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 12/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28262634 | 0.88 | ADORA2A (0.46) | ADORA2AADORA1IRAK4L3MBTL1KDM4E | |
| SCHEMBL19657430 | 0.83 | GAA (0.44) | ADORA2AADORA1IRAK4L3MBTL1GAA | |
| SCHEMBL7516019 | 0.83 | ADORA2A (0.40) | ADORA2AADORA1IRAK4L3MBTL1LMNA | |
| SCHEMBL7515585 | 0.83 | GAA (0.44) | ADORA2AADORA1IRAK4L3MBTL1LMNA | |
| SCHEMBL29002489 | 0.81 | ADORA2A (0.42) | ADORA2AADORA1IRAK4L3MBTL1KDM4E | |
| SCHEMBL15402420 | 0.79 | ALDH1A1 (0.44) | — | |
| SCHEMBL7518894 | 0.79 | ALDH1A1 (0.47) | — | |
| SCHEMBL174293 | 0.79 | ADORA2A (0.45) | ADORA2AADORA1L3MBTL1KDM4EADORA3 | |
| SCHEMBL1224892 | 0.79 | GAA (0.50) | ADORA2AADORA1GAA | |
| SCHEMBL31759474 | 0.79 | ADORA2A (0.49) | ADORA2AADORA1IRAK4KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2580207-B1 | NITROGEN CONTAINING HETEROARYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2017-09-27 | — | — | EP | claimed |
| US-8703768-B2 | Nitrogen containing heteroaryl compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-04-22 | — | — | US | claimed |
| US-8623866-B2 | — | — | 2014-01-07 | — | — | US | claimed |
| EP-2231654-B1 | NEW 2-SUBSTITUTED TIAZOL-4-CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURE AND USE AS MEDICINE | BAYER IP GMBH (DE) | 2013-07-03 | — | — | EP | claimed |
| EP-2580207-A1 | NITROGEN CONTAINING HETEROARYL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2013-04-17 | — | — | EP | claimed |
| EP-2231652-B1 | NOVEL 2-HETARYL THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | Bayer Pharma AG (DE) | 2012-05-30 | — | — | EP | claimed |
| WO-2011154327-A1 | NITROGEN CONTAINING HETEROARYL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-15 | — | — | WO | claimed |
| US-20110306589-A1 | NITROGEN CONTAINING HETEROARYL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-15 | — | — | US | claimed |
| EP-2240457-B1 | NOVEL 2-ARYL-THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | BAYER SCHERING PHARMA AG (DE) | 2011-05-11 | — | — | EP | claimed |
| EP-2070916-A1 | 2-Arylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-17 | — | — | EP | claimed |
| EP-2580207-B1 | NITROGEN CONTAINING HETEROARYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2017-09-27 | — | — | EP | disclosed |
| US-8703768-B2 | Nitrogen containing heteroaryl compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8623866-B2 | — | — | 2014-01-07 | — | — | US | disclosed |
| EP-2231654-B1 | NEW 2-SUBSTITUTED TIAZOL-4-CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURE AND USE AS MEDICINE | BAYER IP GMBH (DE) | 2013-07-03 | — | — | EP | disclosed |
| EP-2580207-A1 | NITROGEN CONTAINING HETEROARYL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2013-04-17 | — | — | EP | disclosed |
| WO-2011154327-A1 | NITROGEN CONTAINING HETEROARYL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-15 | — | — | WO | disclosed |
| EP-2240457-A1 | NOVEL 2-ARYL-THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009074247-A1 | NOVEL 2-ARYL-THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-18 | — | — | WO | disclosed |
| EP-2070916-A1 | 2-Arylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-17 | — | — | EP | disclosed |
| EP-2070925-A1 | New 2-substituted tiazol-4-carboxylic acid derivatives, their manufacture and use as medicine | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306589-A1 | NITROGEN CONTAINING HETEROARYL COMPOUNDS | PDE10A, PDE3A, PDE2A | ADORA2A 66/4885ADORA1 64/4885IRAK4 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.